The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2025-01-01
-Paragraph 39
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard
-URIDate 2025-03-27

Name:	ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Disposal of a subsidiary - Disclosure of net cash inflow arising on disposal of a subsidiary (Details) - USD ($) $ in Thousands		12 Months Ended
	Oct. 01, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disclosure of analysis of single amount of discontinued operations [line items]
Cash flows from losing control of subsidiaries or other businesses		$ 37,764	$ 0	$ 0
ACT Genomics Holdings Company Limited
Disclosure of analysis of single amount of discontinued operations [line items]
Cash consideration	$ 39,873
Less: cash and cash equivalents disposed of	(2,109)
Cash flows from losing control of subsidiaries or other businesses	$ 37,764